Dyphylline aerosol can induce bronchospasm in human asthmatics

Area of Science:

• Pulmonary Medicine
• Pharmacology

Background:

• Asthma is a chronic respiratory disease characterized by airway inflammation and bronchospasm.
• Theophylline derivatives are commonly used for asthma management, but their efficacy via aerosol delivery is less understood.

Purpose of the Study:

• To evaluate the bronchodilator efficacy of aerosolized dihydroxypropyl theophylline (dyphylline) in asthmatic volunteers.
• To assess the onset and severity of bronchospasm following administration of aerosolized dyphylline.

Main Methods:

• Four asthmatic volunteers received single aerosolized doses of dyphylline (250 mg over 5 minutes or 375 mg over 10 minutes).
• Serial spirometry was performed to measure pulmonary function.
• Adverse effects such as bronchospasm were monitored.

Main Results:

• Two subjects experienced marked bronchospasm within ten minutes of administration.
• Another subject developed bronchospasm more gradually.
• One subject showed no significant change in spirometry readings.
• Aerosolized dyphylline did not demonstrate consistent bronchodilator effects.

Conclusions:

• Aerosolized dihydroxypropyl theophylline was not an effective bronchodilator in this study's cohort.
• The administration method and dosage may influence the response to aerosolized dyphylline.
• Further research is needed to clarify the role of aerosolized dyphylline in asthma treatment.